CDKN2A and malignant peripheral nerve sheath tumor: As for genetics and the pathology of MPNST, recurrent genetic mutations have been identified in recent studies, such as loss-of function in NF1, PRC2, TP53, CDKN2A, which may provide new opportunities for therapeutic intervention [33].